Quick Answer
Taysha Gene Therapies, Inc. reported Stockholders Equity of $246.94 million for the year ending 2025.
- Taysha Gene Therapies, Inc. showed an increase of +245.2% in Stockholders Equity from 2024 to 2025.
- This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.57 million | Q2 2020: -$26.79 million | Q3 2020: $267.64 million | Q1 2021: $222.87 million | Q2 2021: $186.50 million | Q3 2021: $140.39 million | Q1 2022: $50.74 million | Q2 2022: $32.51 million | Q3 2022: $10.70 million | Q1 2023: -$14.95 million | Q2 2023: -$37.11 million | Q3 2023: -$49.11 million | Q1 2024: $53.85 million | Q2 2024: $108.87 million | Q3 2024: $88.80 million | Q1 2025: $55.06 million | Q2 2025: $248.73 million | Q3 2025: $218.99 million.
- Historical annual values: Fiscal year 2025: $246.94 million | Fiscal year 2024: $71.53 million | Fiscal year 2023: $74.94 million | Fiscal year 2022: $949.0 thousand | Fiscal year 2021: $95.38 million | Fiscal year 2020: $251.30 million | Fiscal year 2019: -$135.0 thousand | Fiscal year 2019: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: